Marco Donia: Therapeutic Cancer Vaccines – update in Melanoma

Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on LinkedIn:

“Therapeutic Cancer Vaccines: update in Melanoma, March 2024 (slides available, link at the bottom of the post). I was recently invited to the Finnish Melanoma Group 2024 Spring Meeting to provide an update on a field again on the rise: Melanoma Cancer Vaccines.

A quick summary of key topics and key references is provided below:

• Components of a cancer vaccine: Tumor antigens, formulations, immune adjuvants, delivery vehicles.
• Antigens targeted: cancer cell antigens or or antigens of the tumor microenvironment.

Recent results in Metastatic Melanoma:

• IDO/PD-L1 vaccine and phase 3 completed enrolment.
• FixVac, phase 2 ongoing.
• NEO-PV-01.
• EVX-01, phase 2 ongoing.
• Recent Results in high-risk Resected Melanoma: mRNA-4157, phase 3 ongoing.

Want to download and use my slides? You can do via this link (email required).

If you know other vaccines for melanoma in development, please comment and I will update the post! Thanks to the Finnish Melanoma Group and its (now, past) chair, Micaela Hernberg from HUS Helsinki University Hospital, for the invite and the great scientific exchange.”

Source: Marco Donia/LinkedIn